The 2021 WHO Classification of Tumors of the Central Nervous System: a summary

Neuro-Oncology - Tập 23 Số 8 - Trang 1231-1251 - 2021
David N. Louis1, Arie Perry2, Pieter Wesseling3,4, Daniel J. Brat5, Ian A. Cree6, Dominique Figarella‐Branger7, Cynthia Hawkins8, Ho‐Keung Ng9, Stefan M. Pfister10, Guido Reifenberger11, Riccardo Soffietti12, Andreas von Deimling13,14, David W. Ellison15
1Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA,
2Department of Pathology, University of California San Francisco, San Francisco, California, USA
3Department of Pathology, Amsterdam University Medical Centers/VUmc, Amsterdam, the Netherlands
4Laboratory for Childhood Cancer Pathology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
5Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois USA
6International Agency for Research on Cancer, World Health Organization, Lyon, France
7Service d’Anatomie Pathologique et de Neuropathologie, APHM, CNRS, Institut de Neurophysiopathologie, Hôpital de la Timone, Aix-Marseille University, Marseille, France
8Department of Paediatric Laboratory Medicine, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
9Department of Anatomical and Cellular Pathology, Chinese University of Hong Kong, Hong Kong, China
10Hopp Children’s Cancer Center at the NCT Heidelberg (KiTZ), Division of Pediatric Neurooncology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), and Department of Pediatric Oncology, Hematology and Immunology, Heidelberg University Hospital, Heidelberg, Germany
11Institute of Neuropathology, University Hospital Düsseldorf and Medical Faculty, Heinrich Heine University Düsseldorf, and German Cancer Consortium (DKTK) Partner Site Essen/Düsseldorf, Düsseldorf, Germany
12Department of Neurology and Neuro-Oncology, University of Turin Medical School, Turin, Italy
13Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany
14Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University, Heidelberg, Germany
15Department of Pathology, St Jude Children’s Research Hospital, Memphis, Tennessee, USA

Tóm tắt

AbstractThe fifth edition of the WHO Classification of Tumors of the Central Nervous System (CNS), published in 2021, is the sixth version of the international standard for the classification of brain and spinal cord tumors. Building on the 2016 updated fourth edition and the work of the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy, the 2021 fifth edition introduces major changes that advance the role of molecular diagnostics in CNS tumor classification. At the same time, it remains wedded to other established approaches to tumor diagnosis such as histology and immunohistochemistry. In doing so, the fifth edition establishes some different approaches to both CNS tumor nomenclature and grading and it emphasizes the importance of integrated diagnoses and layered reports. New tumor types and subtypes are introduced, some based on novel diagnostic technologies such as DNA methylome profiling. The present review summarizes the major general changes in the 2021 fifth edition classification and the specific changes in each taxonomic category. It is hoped that this summary provides an overview to facilitate more in-depth exploration of the entire fifth edition of the WHO Classification of Tumors of the Central Nervous System.

Từ khóa


Tài liệu tham khảo

WHO Classification of Tumours Editorial Board., 2021, World Health Organization Classification of Tumours of the Central Nervous System, 5th ed.

Zulch, 1979, Histological Typing of Tumours of the Central Nervous System

Kleihues, 1993, Histological Typing of Tumours of the Central Nervous System, 10.1007/978-3-642-84988-6

Kleihues, 2000, World Health Organization Classification of Tumours of the Nervous System

Louis, 2007, World Health Organization Histological Classification of Tumours of the Central Nervous System, 4th ed.

Louis, 2016, World Health Organization Classification of Tumours of the Central Nervous System, 4th ed.

Louis, 2017, cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification, Brain Pathol., 27, 851, 10.1111/bpa.12457

Louis, 2017, Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy, Acta Neuropathol., 133, 1, 10.1007/s00401-016-1646-x

Louis, 2018, cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant, Acta Neuropathol., 135, 639, 10.1007/s00401-018-1826-y

Ellison, 2019, cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation, Acta Neuropathol., 137, 683, 10.1007/s00401-019-01987-0

Brat, 2018, cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”, Acta Neuropathol., 136, 805, 10.1007/s00401-018-1913-0

Louis, 2018, cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC), Acta Neuropathol, 135, 481, 10.1007/s00401-018-1808-0

Louis, 2019, cIMPACT-NOW: a practical summary of diagnostic points from Round 1 updates, Brain Pathol., 29, 469, 10.1111/bpa.12732

Louis, 2020, cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading, Brain Pathol., 30, 844, 10.1111/bpa.12832

Brat, 2020, cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas, Acta Neuropathol, 139, 603, 10.1007/s00401-020-02127-9

Ellison, 2020, cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors, Brain Pathol., 30, 863, 10.1111/bpa.12866

Bruford, 2020, Guidelines for human gene nomenclature, Nature genetics, 52, 754, 10.1038/s41588-020-0669-3

den Dunnen, 2016, HGVS recommendations for the description of sequence variants: 2016 update, Hum Mutat., 37, 564, 10.1002/humu.22981

McGowan-Jordan, 2020, ISCN 2020: An International System for Human Cytogenomic Nomenclature, 10.1159/isbn.978-3-318-06867-2

Louis, 2017, Grading of diffuse astrocytic gliomas: Broders, Kernohan, Zülch, the WHO… and Shakespeare, Acta Neuropathol., 134, 517, 10.1007/s00401-017-1765-z

von Deimling, 2018, Grading of diffuse astrocytic gliomas: a review of studies before and after the advent of IDH testing, Semin Neurol., 38, 19, 10.1055/s-0038-1636430

Louis, 2014, International Society of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading, Brain Pathol, 24, 429, 10.1111/bpa.12171

Aldape, 2017, Integrating molecular markers into the World Health Organization classification of CNS tumors: a survey of the neuro-oncology community, Neuro Oncol., 19, 336

Andreiuolo, 2016, A global view on the availability of methods and information in the neuropathological diagnostics of CNS tumors: results of an international survey among neuropathological units, Brain Pathol., 26, 551, 10.1111/bpa.12383

Santosh, 2019, ISNO consensus guidelines for practical adaptation of the WHO 2016 classification of adult diffuse gliomas, Neurol India, 67, 173, 10.4103/0028-3886.253572

Sonoda, 2019, Practical procedures for the integrated diagnosis of astrocytic and oligodendroglial tumors, Brain Tumor Pathol, 36, 56, 10.1007/s10014-019-00337-y

Capper, 2018, DNA methylation-based classification of central nervous system tumours, Nature., 555, 469, 10.1038/nature26000

Capper, 2018, Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience, Acta Neuropathol., 136, 181, 10.1007/s00401-018-1879-y

Jaunmuktane, 2019, Methylation array profiling of adult brain tumours: diagnostic outcomes in a large, single centre, Acta Neuropathol Commun, 7, 24, 10.1186/s40478-019-0668-8

Priesterbach-Ackley, 2020, Brain tumour diagnostics using a DNA methylation-based classifier as a diagnostic support tool, Neuropathol Appl Neurobiol, 46, 478, 10.1111/nan.12610

Louis, 2019, Data sets for the reporting of tumors of the central nervous system: Recommendations fro the International Collaboration on Cancer Reporting, Arch Pathol Lab Med, 144, 196, 10.5858/arpa.2018-0565-OA

Siegfried, 2019, EWSR1-PATZ1 gene fusion may define a new glioneuronal tumor entity, Brain Pathol., 29, 53, 10.1111/bpa.12619

Stichel, 2019, Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions, Acta Neuropathol., 138, 827, 10.1007/s00401-019-02039-3

Burel-Vandenbos, 2020, A polyphenotypic malignant paediatric brain tumour presenting a MN1-PATZ1 fusion, no epigenetic similarities with CNS High-Grade Neuroepithelial Tumour with MN1 Alteration (CNS HGNET-MN1) and related to PATZ1-fused sarcomas, Neuropathol Appl Neurobiol., 46, 506, 10.1111/nan.12626

Sievers, 2021, A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR, Neuro Oncol, 23, 34, 10.1093/neuonc/noaa251

Tesileanu, 2020, Survival of diffuse astrocytic glioma, IDH1/2-wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria, Neuro Oncol, 22, 515, 10.1093/neuonc/noz200

Clarke, 2020, Infant high-grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes, Cancer Discov., 10, 942, 10.1158/2159-8290.CD-19-1030

Guerreiro Stucklin, 2019, Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas, Nat Commun., 10, 4343, 10.1038/s41467-019-12187-5

Pajtler, 2015, Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups, Cancer Cell., 27, 728, 10.1016/j.ccell.2015.04.002

Ellison, 2011, Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts, J Negat Results Biomed, 10, 7, 10.1186/1477-5751-10-7

Vera-Bolanos, 2015, Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients, Neuro Oncol, 17, 440, 10.1093/neuonc/nou162

Taylor, 2012, Molecular subgroups of medulloblastoma: the current consensus, Acta Neuropathol., 123, 465, 10.1007/s00401-011-0922-z

Schwalbe, 2017, Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study, Lancet Oncol., 18, 958, 10.1016/S1470-2045(17)30243-7

Cavalli, 2017, Intertumoral heterogeneity within medulloblastoma subgroups, Cancer Cell, 31, 737, 10.1016/j.ccell.2017.05.005

Sharma, 2019, Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes, Acta Neuropathol., 138, 309, 10.1007/s00401-019-02020-0

Kumar, 2020, Medulloblastoma genomics in the modern molecular era, Brain Pathol., 30, 679, 10.1111/bpa.12804

Hovestadt, 2020, Medulloblastomics revisited: biological and clinical insights from thousands of patients, Nat Rev Cancer., 20, 42, 10.1038/s41568-019-0223-8

Robinson, 2018, Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial, Lancet Oncol., 19, 768, 10.1016/S1470-2045(18)30204-3

Mynarek, 2020, Nonmetastatic medulloblastoma of early childhood: results from the prospective clinical trial HIT-2000 and an extended validation cohort, J Clin Oncol, 38, 2028, 10.1200/JCO.19.03057

Robinson, 2020, Genomics paves the way for better infant medulloblastoma therapy, J Clin Oncol, 38, 2010, 10.1200/JCO.20.00593

Eberhart, 2002, Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study, Cancer., 94, 552, 10.1002/cncr.10189

McManamy, 2003, Morphophenotypic variation predicts clinical behavior in childhood non-desmoplastic medulloblastomas, J Neuropathol Exp Neurol, 62, 627, 10.1093/jnen/62.6.627

McManamy, 2007, Nodule formation and desmoplasia in medulloblastomas-defining the nodular/desmoplastic variant and its biological behavior, Brain Pathol, 17, 151, 10.1111/j.1750-3639.2007.00058.x

Massimino, 2013, Histological variants of medulloblastoma are the most powerful clinical prognostic indicators, Pediatr Blood Cancer., 60, 210, 10.1002/pbc.24225

Ellison, 2011, Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups, Acta Neuropathol., 121, 381, 10.1007/s00401-011-0800-8

Thomas, 2020, Desmoplastic myxoid tumor, SMARCB1-mutant: clinical, histopathological and molecular characterization of a pineal region tumor encountered in adolescents and adults, Acta Neuropathol., 139, 277, 10.1007/s00401-019-02094-w

Lee, 2019, Recurrent KBTBD4 small in-frame insertions and absence of DROSHA deletion or DICER1 mutation differentiate pineal parenchymal tumor of intermediate differentiation (PPTID) from pineoblastoma, Acta Neuropathol., 137, 851, 10.1007/s00401-019-01990-5

Pfaff, 2020, Molecular subgrouping of primary pineal parenchymal tumors reveals distinct subtypes correlated with clinical parameters and genetic alterations, Acta Neuropathol., 139, 243, 10.1007/s00401-019-02101-0

Li, 2020, Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study, Acta Neuropathol., 139, 223, 10.1007/s00401-019-02111-y

Vaubel, 2016, Meningiomas with rhabdoid features lacking other histologic features of malignancy: a study of 44 cases and review of the literature, J Neuropathol Exp Neurol, 75, 44, 10.1093/jnen/nlv006

Sahm, 2016, TERT promoter mutations and risk of recurrence in meningioma, J Natl Cancer Inst, 108, 1, 10.1093/jnci/djv377

Sievers, 2020, CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas, Acta Neuropathol., 140, 409, 10.1007/s00401-020-02188-w

Gauchotte, 2020, Prognostic value of histopathological features and loss of H3K27me3 immunolabeling in anaplastic meningioma: a multicenter retrospective study, J Neuropathol Exp Neurol, 79, 754, 10.1093/jnen/nlaa038

Nassiri, 2019, DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management, Neuro Oncol, 21, 901, 10.1093/neuonc/noz061

Müller, 2019, Craniopharyngioma, Nat Rev Dis Primers., 5, 75, 10.1038/s41572-019-0125-9

Holsken, 2016, Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles, Acta Neuropathol Commun, 4, 20, 10.1186/s40478-016-0287-6

Mete, 2013, Spindle cell oncocytomas and granular cell tumors of the pituitary are variants of pituicytoma, Am J Surg Pathol, 37, 1694, 10.1097/PAS.0b013e31829723e7

El Hussein, 2017, Pituicytoma: review of commonalities and distinguishing features among TTF-1 positive tumors of the central nervous system, Ann Diagn Pathol, 29, 57, 10.1016/j.anndiagpath.2017.05.004

Rindi, 2018, A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal, Mod Pathol., 31, 1770, 10.1038/s41379-018-0110-y

Thông tin
Thông tin xuất bản

Neuro-Oncology

Tập 23 Số 8

1231-1251

Thông tin tác giả